PTC Therapeutics, Inc. (PTCT)
63.80
+1.24
(+1.98%)
USD |
NASDAQ |
Oct 09, 13:22
PTC Therapeutics Net Income (Quarterly) : 83.50M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.50M |
| March 31, 2026 | -2.809M |
| December 31, 2025 | -134.96M |
| September 30, 2025 | 15.90M |
| June 30, 2025 | -64.85M |
| March 31, 2025 | 866.56M |
| December 31, 2024 | -65.89M |
| September 30, 2024 | -106.65M |
| June 30, 2024 | -99.18M |
| March 31, 2024 | -91.58M |
| December 31, 2023 | -155.79M |
| September 30, 2023 | -132.97M |
| June 30, 2023 | -198.88M |
| March 31, 2023 | -138.96M |
| December 31, 2022 | -170.89M |
| September 30, 2022 | -109.32M |
| June 30, 2022 | -152.09M |
| March 31, 2022 | -126.73M |
| December 31, 2021 | -143.26M |
| September 30, 2021 | -133.62M |
| June 30, 2021 | -118.37M |
| March 31, 2021 | -128.64M |
| December 31, 2020 | -74.35M |
| September 30, 2020 | -69.69M |
| June 30, 2020 | -181.43M |
| Date | Value |
|---|---|
| March 31, 2020 | -112.69M |
| December 31, 2019 | -77.68M |
| September 30, 2019 | -60.00M |
| June 30, 2019 | -41.79M |
| March 31, 2019 | -72.11M |
| December 31, 2018 | -48.33M |
| September 30, 2018 | -50.97M |
| June 30, 2018 | -9.52M |
| March 31, 2018 | -19.26M |
| December 31, 2017 | 1.27M |
| September 30, 2017 | -33.74M |
| June 30, 2017 | -17.48M |
| March 31, 2017 | -29.06M |
| December 31, 2016 | -26.80M |
| September 30, 2016 | -35.17M |
| June 30, 2016 | -38.91M |
| March 31, 2016 | -41.23M |
| December 31, 2015 | -50.95M |
| September 30, 2015 | -43.22M |
| June 30, 2015 | -38.36M |
| March 31, 2015 | -37.92M |
| December 31, 2014 | -27.27M |
| September 30, 2014 | -27.28M |
| June 30, 2014 | -25.10M |
| March 31, 2014 | -14.10M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Biogen, Inc. | 97.50M |
| BioMarin Pharmaceutical, Inc. | 44.76M |
| Arcturus Therapeutics Holdings, Inc. | -23.78M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 360.52M |
| Total Expenses (Quarterly) | 277.02M |
| EPS Diluted (Quarterly) | 0.9178 |
| Enterprise Value | 3.680B |
| Gross Profit Margin (Quarterly) | 91.19% |
| Profit Margin (Quarterly) | 23.16% |
| Earnings Yield | -0.93% |
| Operating Earnings Yield | 2.14% |
| Normalized Earnings Yield | -1.052 |